RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Ral (Ras like) leads an important proto‐oncogenic signaling pathway down‐stream of Ras. In this work, RalA was found to be significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues as compared to non‐malignant samples. Other elements of RalA pathway such as RalBP1 and RalGDS were also expressed at higher levels in malignant samples. Inhibition of RalA by gene‐specific silencing caused a robust decrease in the viability and invasiveness of HCC cells. Additionally, the use of geranyl–geranyl transferase inhibitor (GGTI, an inhibitor of Ral activation) and Aurora kinase inhibitor II resulted in a significant decrease in the proliferation of HCC cells. Furthermore, RalA activation was found to be at a higher level of activation in HCC stem cells that express CD133. Transgenic mouse model for HCC (FXR‐Knockout) also revealed an elevated level of RalA‐GTP in the liver tumors as compared to background animals. Finally, subcutaneous mouse model for HCC confirmed effectiveness of inhibition of aurora kinase/RalA pathway in reducing the tumorigenesis of HCC cells in vivo. In conclusion, RalA overactivation is an important determinant of malignant phenotype in differentiated and stem cells of HCC and can be considered as a target for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ral-GTPases: approaching their 15 minutes of fame.
Feig, L. A. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00152-1 · Cited by 249
Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
Lim, K.-H., Brady, D. C., Kashatus, D. F., Ancrile, B. B., Der, C. J., Cox, A. D., & Counter, C. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00916-08 · Cited by 126
Cited by
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
“In most models, RALA is the dominant isoform driving tumor progression and metastasis, including in hepatocellular carcinoma (Ezzeldin et al., 2014), malignant peripheral nerve sheath tumors (Bodempudi et al., 2009), and ovarian cancer (Wang et al., 2013).”
BackgroundRal GTPases: crucial mediators of exocytosis and tumourigenesis
Shirakawa, R., & Horiuchi, H. (2015) · Journal of Biochemistry · doi:10.1093/jb/mvv029 · Cited by 76
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
Self-citationThe RAL Enigma: Distinct Roles of RALA and RALB in Cancer
Richardson, D. S., Spehar, J. M., Han, D. T., Chakravarthy, P. A., & Sizemore, S. T. (2022) · Cells · doi:10.3390/cells11101645 · Cited by 31
Wagner, M., Skorobogatko, Y., Pode-Shakked, B., Powell, C. M., Alhaddad, B., Seibt, A., Barel, O., Heimer, G., Hoffmann, C., Demmer, L. A., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.01.002 · Cited by 31
Wang, D., Huang, Z., Li, L., Yuan, Y., Xiang, L., Wu, X., Ni, C., & Yu, W. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10599 · Cited by 7
Metadata
- Authors
- Ezzeldin, M., Borrego-Diaz, E., Taha, M., Esfandyari, T., Wise, A. L., Peng, W., Rouyanian, A., Asvadi Kermani, A., Soleimani, M., Patrad, E., Lialyte, K., Wang, K., Williamson, S., Abdulkarim, B., Olyaee, M., & Farassati, F.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2014-04-13
- Volume
- 8
- Issue
- 5
- Pages
- 1043-1053
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2089695492
- Cited by
- 46
- References
- 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.